CIRM grantees at Children's Hospital Los Angeles and the University of Southern California have succeeded in growing normal-looking small intestines in mice.
In a press release, the senior author Tracy Grikscheit said:
At the 18th Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, two members of CIRM's HIV/AIDS Disease Team led by John Zaia at City of Hope presented new research showing the team's progress toward the clinic.
Advanced Cell Technology has filed an application with the FDA to begin an early phase trial of an embryonic stem cell-based therapy for macular degeneration. If the company name sounds familiar, that's because it's the same company that on November 22 received FDA approval to begin a trial for Stargardt's macular degeneration. Both trials are testing the same cells. In a press release, the company said:
The FDA has given the green light to the second trial based on embryonic stem cells - this one for a genetic form of blindness called Stargardt's Macular Degeneration. The treatment, developed by Advanced Cell Technology, involves replacing the the layer of the retina damaged by the disease, called the retinal pigment epithelium, with new RPE cells derived from embryonic stem cells.
 |
| The Lorry I. Lokey Stem Cell Research Building |
 |
| On left and right, Berkeley Stem Cell Center co-directors David Schaffer and Randy Shekman, and center, |
